Matrixyl (Palmitoyl Pentapeptide)

Palmitoyl pentapeptide-4 (trade name Matrixyl, developed by Sederma SAS, France) is a synthetic lipopeptide consisting of the pentapeptide KTTKS (Lys-Thr-Thr-Lys-Ser) coupled to a 16-carbon palmitoyl fatty acid chain. It functions as a matrikine — a bioactive signaling fragment that mimics collagen-derived propeptide sequences to stimulate dermal extracellular matrix renewal.

The KTTKS sequence was identified by Katayama et al. (1993, J Biol Chem, PMID 8486721) as residues 212–216 of the C-terminal propeptide of type I procollagen. During normal fibril assembly, propeptide domains are enzymatically cleaved extracellularly; KTTKS is the minimum fragment capable of stimulating collagen I, collagen III, and fibronectin synthesis in mesenchymal cells dose- and time-dependently, consistent with a feedback regulatory role in ECM homeostasis.

• Skin penetration: the palmitoyl modification enables percutaneous delivery absent in the unmodified peptide. Choi et al. (2014, Biomol Ther, PMID 25143811) demonstrated that pal-KTTKS distributes into the stratum corneum, viable epidermis, and dermis in vitro, while unmodified KTTKS is undetectable in any skin layer. The lipid tail is thought to intercalate into stratum corneum lipid bilayers. • TGF-β pathway: Tsai et al. (2007, J Orthop Res, DOI 10.1002/jor.20455) showed KTTKS upregulates transforming growth factor-beta in fibroblasts, which stabilizes alpha-1 procollagen mRNA and sustains collagen I expression. • Protease inhibition: Tałałaj et al. (2019, Molecules, PMID 31618846) found pal-KTTKS potently inhibits plasmin, suggesting a possible ECM-protective effect; this activity has not been evaluated in cosmetic clinical trials.

The primary published clinical evidence is Robinson et al. (2005, Int J Cosmetic Sci, PMID 18492182; DOI 10.1111/j.1467-2494.2005.00261.x), a 12-week, double-blind, placebo-controlled, split-face randomized clinical trial conducted by Procter & Gamble researchers. Ninety-three Caucasian women aged 35–55 applied a moisturizer containing 3 ppm pal-KTTKS to one cheek and a matched vehicle control to the other, twice daily. Both quantitative profilometric image analysis and expert grader assessment showed statistically significant reduction in wrinkles and fine lines on the active side relative to placebo. Subjects' self-assessments corroborated instrumental findings. No clinically significant adverse events were reported. The research team noted that 3 ppm pal-KTTKS performed comparably to 700 ppm retinol in exploratory testing with superior tolerability; this comparison has not been independently replicated.

A 2023 double-blind RCT by Indonesian investigators enrolled 21 female subjects aged 26–55 and compared a palmitoyl pentapeptide-4 cream, an acetylhexapeptide-3 cream, and placebo over eight weeks for crow's feet wrinkles, reporting improvements in both active arms versus placebo. The small sample size and single-center design limit generalizability.

A 2011 narrative review (Abu Samah and Heard, Cardiff University; Int J Cosmetic Sci 33:483–490, PMID 21535443) concluded there is "a sound in vitro basis for action on fibroblasts" but identified "relatively few clinical studies" and "a surprising absence of in vitro skin penetration data." The penetration gap was partly addressed by Choi et al. (2014, PMID 25143811), confirming pal-KTTKS distributes across skin layers in vitro while unmodified KTTKS does not.

No large independent multi-center RCTs (n > 200) have been published as of mid-2026. Most available clinical data originates from or was funded by the manufacturer.

Typical dosage: Topical application (daily).

In the Robinson et al. (2005) clinical trial — the only peer-reviewed RCT establishing a human efficacy benchmark — the concentration was 3 ppm (approximately 0.0003% w/w) of palmitoyl pentapeptide-4 incorporated into a moisturizer and applied to the face twice daily (morning and evening) for 12 weeks. This is the reference concentration in the cosmetic ingredient literature.

Commercially, pal-KTTKS is supplied by Sederma under the Matrixyl trade name as a 100 ppm solution in a butylene glycol/water carrier. Cosmetic formulators typically incorporate the commercial stock at 2–8% in finished products (serums, creams, eye treatments), yielding approximately 2–8 ppm of the active peptide in the final formulation. Twice-daily topical application to cleansed facial skin is standard practice, consistent with the clinical trial protocol.

No dose-ranging, minimum effective dose, or maximum-dose studies have been published in the peer-reviewed literature. Duration of use in the published trial was 12 weeks; continuous long-term use is typical in cosmetic practice without a defined upper limit or established treatment interval. No parenteral or injectable formulations have been studied or approved.

This information is provided for educational and reference purposes only and does not constitute medical advice. Individuals seeking therapeutic guidance regarding skin aging treatments should consult a licensed dermatologist or qualified healthcare professional.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

Matrixyl 3000 (Sederma) is the best-known combination formulation, pairing palmitoyl pentapeptide-4 with palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 to target complementary extracellular matrix components (collagen I, elastin fragments). Manufacturer-sponsored data report approximately 45% reduction in the surface area occupied by deep wrinkles after two months; independent peer-reviewed validation of this specific combination does not exist.

Pal-KTTKS is commonly co-formulated with the following actives in commercial products, with rationales that are biologically plausible but supported only by individual-ingredient evidence or anecdote at the combination level:

• Retinol — stimulates collagen via nuclear RAR/RXR receptors, providing mechanistic complementarity with the extracellular matrikine pathway of pal-KTTKS. • Vitamin C (ascorbic acid) — serves as a cofactor for collagen prolyl hydroxylase and provides antioxidant protection. • Acetylhexapeptide-3 (Argireline) — inhibits neurotransmitter release at the neuromuscular junction, targeting dynamic expression wrinkles through a different mechanism. • Hyaluronic acid — hydration; no mechanistic conflict. • Niacinamide — supports barrier function.

No published controlled trial has compared any of these multi-ingredient combinations against pal-KTTKS monotherapy. All combination strategies at the finished cosmetic formulation level rest on anecdotal evidence and extrapolation from single-ingredient studies.

Matrixyl (Palmitoyl Pentapeptide) is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Very safe for topical use. Rare: mild irritation

The Cosmetic Ingredient Review (CIR) Expert Panel assessed palmitoyl pentapeptide-4 alongside related variants and concluded the ingredients are safe in cosmetics at present practices of use and concentration. The compound is used at trace levels (typically 2–10 ppm of the active peptide in finished formulations).

In the Robinson et al. (2005) 12-week RCT, pal-KTTKS at 3 ppm applied twice daily was explicitly described as "well tolerated by the skin," with no clinically significant adverse events reported across 93 subjects.

Tałałaj et al. (2019, Molecules, PMID 31618846) confirmed no cytotoxicity toward human dermal fibroblasts at 1, 10, and 100 μM in the MTT viability assay, and found no evidence of cytotoxicity across 30 novel analogues synthesized for comparison.

Preclinical testing of the undiluted commercial Matrixyl solution (100 ppm) classified it as a moderate ocular irritant; at finished-product concentrations (approximately 0.0001–0.001% active peptide), the CIR assessment regards ocular exposure risk as negligible. No dermal sensitization or contact allergy has been identified as a concern in the published safety literature.

Choi et al. (2014, PMID 25143811) demonstrated pal-KTTKS does not permeate through full-thickness hairless mouse skin into the receptor solution in vitro, consistent with negligible systemic absorption at cosmetic use concentrations.

No drug interactions, serious adverse events, or contraindications for topical cosmetic use are described in the peer-reviewed record. Palmitoyl pentapeptide-4 is a cosmetic ingredient; it is not approved as a pharmaceutical drug by any regulatory agency and has not been evaluated for injection, mucosal, or oral administration.